Discovery of WNT9B Gene Mutation Significantly Increases Prostate Cancer Risk
/0 Comments/in Observational/by MaxRethinking Treatment for mHSPC: Insights from Dr. Karim Fizazi
/0 Comments/in Expert Insights, Observational, Retrospective studies/by MaxRetrospective study: Real-World Effectiveness of Apalutamide in mHSPC
/0 Comments/in Observational, Retrospective studies/by MaxNew Blood Test Predicts Prognosis for Advanced Prostate Cancer Patients
/0 Comments/in Observational, Post-hoc/by MaxBone-Modifying Agents Linked to Improved Survival in Advanced Prostate Cancer
/0 Comments/in Observational, Retrospective studies/by MaxMatching-Adjusted Comparison of PARPi Therapies for mCRPC: Talazoparib + Enzalutamide Wins
/0 Comments/in Clinical Trial, Metastatic, Observational, Post-hoc, Retrospective studies/by MaxRethinking the “Lower is Better” Approach to LDL-C: Examining the Relationship Between Low LDL-C and Prostate Cancer Risk in Non-Hypertensive Men
/0 Comments/in Observational, Retrospective studies/by MaxThe Role of HSD3B1 in Prostate Cancer Progression and Treatment
/0 Comments/in Observational, Retrospective studies/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
abiraterone acetate ADC ADT AI ai in healthcare alphafold antibody-drug conjugate apalutamide artificial intelligence ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy cancer treatment cancer vaccine clinical trial clinical trials crispr darolutamide drug repurposing drug resistance enzalutamide hormone therapy immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology neuroendocrine prostate cancer oncology oncolytic virus personalized medicine prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy targeted drug delivery theranostics
Latest Posts
- Predictive Oncology’s Breakthrough in Drug Repurposing Offers Hope for Patients April 16, 2025
- Phase 1 Soon Recruiting: MK-2400 (Ifinatamab Deruxtecan) for Metastatic Prostate Cancer April 15, 2025
- Newsletter 15/2025 April 13, 2025
- Phase 1 Trial: The COSMYC Trial, ZEN-3694 Combination With BAT April 11, 2025